Cardiac toxicity secondary to long term treatment with chloroquine.
作者信息
Cervera A, Espinosa G, Font J, Ingelmo M
出版信息
Ann Rheum Dis. 2001 Mar;60(3):301. doi: 10.1136/ard.60.3.301.
Abstract
摘要
相似文献
1
Cardiac toxicity secondary to long term treatment with chloroquine.
Ann Rheum Dis. 2001 Mar;60(3):301. doi: 10.1136/ard.60.3.301.
2
Chloroquine-induced cardiomyopathy-echocardiographic features.
J Am Soc Echocardiogr. 2005 Apr;18(4):383-7. doi: 10.1016/j.echo.2004.09.029.
3
[Ocular and cardiac toxicity by chloroquine].
Rev Med Chil. 2011 Oct;139(10):1384-6. Epub 2012 Jan 3.
4
[Heart conduction disorders in long-term treatment with chloroquine. Two new cases].
Presse Med. 1992;21(17):800-4.
5
[Reversible restrictive cardiomyopathy secondary to chloroquine].
Med Clin (Barc). 2007 Jun 23;129(4):157. doi: 10.1157/13107491.
6
Restrictive Cardiomyopathy Associated With Long-Term Use of Hydroxychloroquine for Systemic Lupus Erythematosus.
J Pharm Pract. 2017 Oct;30(5):571-575. doi: 10.1177/0897190016655726. Epub 2016 Jun 26.
7
Restrictive cardiomyopathy caused by chloroquine.
Br Heart J. 1993 May;69(5):451-2. doi: 10.1136/hrt.69.5.451.
8
Heart transplantation in a patient with chloroquine-induced cardiomyopathy.
J Heart Lung Transplant. 2004 Feb;23(2):252-5. doi: 10.1016/S1053-2498(03)00108-6.
9
Restrictive cardiomyopathy secondary to hydroxychloroquine therapy.
J Rheumatol. 2009 Feb;36(2):440-1. doi: 10.3899/jrheum.080305.
10
Chloroquine cardiomyopathy with conduction disorders.
Heart. 1999 Feb;81(2):221-3. doi: 10.1136/hrt.81.2.221.
引用本文的文献
1
Repurposing Chloroquine Against Multiple Diseases With Special Attention to SARS-CoV-2 and Associated Toxicity.
Front Pharmacol. 2021 Apr 12;12:576093. doi: 10.3389/fphar.2021.576093. eCollection 2021.
2
The spectrum of lupus myocarditis: from asymptomatic forms to cardiogenic shock.
Heart Fail Rev. 2021 May;26(3):553-560. doi: 10.1007/s10741-020-10054-w. Epub 2020 Nov 19.
3
Cardiac Involvement of COVID-19: A Comprehensive Review.
Am J Med Sci. 2021 Jan;361(1):14-22. doi: 10.1016/j.amjms.2020.10.002. Epub 2020 Oct 6.
4
Hydroxychloroquine: a comprehensive review and its controversial role in coronavirus disease 2019.
Ann Med. 2021 Dec;53(1):117-134. doi: 10.1080/07853890.2020.1839959.
5
Drug-induced 'Torsade de Pointes' in a COVID-19 patient despite discontinuation of chloroquine. Importance of its long half-life: a case report.
Eur Heart J Case Rep. 2020 Jul 21;4(FI1):1-5. doi: 10.1093/ehjcr/ytaa218. eCollection 2020 Oct.
6
Coronavirus disease-19 and cardiovascular disease: A risk factor or a risk marker?
Rev Med Virol. 2021 May;31(3):e2172. doi: 10.1002/rmv.2172. Epub 2020 Sep 22.
7
Guidance for cardiac electrophysiology during the COVID-19 pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.
Heart Rhythm. 2020 Sep;17(9):e233-e241. doi: 10.1016/j.hrthm.2020.03.028. Epub 2020 Apr 1.
8
Guidance for Cardiac Electrophysiology During the COVID-19 Pandemic from the Heart Rhythm Society COVID-19 Task Force; Electrophysiology Section of the American College of Cardiology; and the Electrocardiography and Arrhythmias Committee of the Council on Clinical Cardiology, American Heart Association.
Circulation. 2020 May 26;141(21):e823-e831. doi: 10.1161/CIRCULATIONAHA.120.047063. Epub 2020 Mar 31.
9
Cardiac Complications Attributed to Chloroquine and Hydroxychloroquine: A Systematic Review of the Literature.
Drug Saf. 2018 Oct;41(10):919-931. doi: 10.1007/s40264-018-0689-4.
10
Current and Future Use of Chloroquine and Hydroxychloroquine in Infectious, Immune, Neoplastic, and Neurological Diseases: A Mini-Review.
Clin Drug Investig. 2018 Aug;38(8):653-671. doi: 10.1007/s40261-018-0656-y.
Zotero 插件